These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
481 related articles for article (PubMed ID: 20225018)
1. Phenotype variations in early onset Pompe disease: diagnosis and treatment results with Myozyme. Pascual SI Adv Exp Med Biol; 2009; 652():39-46. PubMed ID: 20225018 [TBL] [Abstract][Full Text] [Related]
2. Pompe disease: early diagnosis and early treatment make a difference. Chien YH; Hwu WL; Lee NC Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029 [TBL] [Abstract][Full Text] [Related]
3. Pompe disease: current state of treatment modalities and animal models. Geel TM; McLaughlin PM; de Leij LF; Ruiters MH; Niezen-Koning KE Mol Genet Metab; 2007 Dec; 92(4):299-307. PubMed ID: 17826266 [TBL] [Abstract][Full Text] [Related]
4. Genotype, phenotype and treatment outcomes of 17 Malaysian patients with infantile-onset Pompe disease and the identification of 3 novel GAA variants. Chan MY; Jalil JA; Yakob Y; Wahab SAA; Ali EZ; Khalid MKNM; Leong HY; Chew HB; Sivabalakrishnan JB; Ngu LH Orphanet J Rare Dis; 2023 Aug; 18(1):231. PubMed ID: 37542277 [TBL] [Abstract][Full Text] [Related]
5. Novel GAA sequence variant c.1211 A>G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease. Nilsson MI; Kroos MA; Reuser AJ; Hatcher E; Akhtar M; McCready ME; Tarnopolsky MA Gene; 2014 Mar; 537(1):41-5. PubMed ID: 24384324 [TBL] [Abstract][Full Text] [Related]
7. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease. Wang Z; Okamoto P; Keutzer J Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919 [TBL] [Abstract][Full Text] [Related]
8. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy. van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258 [TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation. But WM; Lee SH; Chan AO; Lau GT Hong Kong Med J; 2009 Dec; 15(6):474-7. PubMed ID: 19966354 [TBL] [Abstract][Full Text] [Related]
10. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease. Lacaná E; Yao LP; Pariser AR; Rosenberg AS Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):30-9. PubMed ID: 22253234 [TBL] [Abstract][Full Text] [Related]
11. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond. Kishnani PS; Beckemeyer AA Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093 [TBL] [Abstract][Full Text] [Related]
12. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients. Bernstein DL; Bialer MG; Mehta L; Desnick RJ Mol Genet Metab; 2010; 101(2-3):130-3. PubMed ID: 20638881 [TBL] [Abstract][Full Text] [Related]
13. Significance of early diagnosis and treatment of adult late-onset Pompe disease on the effectiveness of enzyme replacement therapy in improving muscle strength and respiratory function: a case report. Mir M; Rouhani K; Rouhani K; Hassani M; Damirchi M; Yazdansetad S; Aghaei M J Med Case Rep; 2024 Oct; 18(1):486. PubMed ID: 39375771 [TBL] [Abstract][Full Text] [Related]
14. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease. Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884 [TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy and immunotherapy lead to significant functional improvement in two children with Pompe disease: a case report. Castellar-Leones SM; Ortiz-Corredor F; Manrique-Hernández D; Sánchez-Peñarete D; Ruiz-Ospina E; Soto-Peña D; Correa-Arrieta C J Med Case Rep; 2024 Jul; 18(1):328. PubMed ID: 39020349 [TBL] [Abstract][Full Text] [Related]
16. A novel mutation of the GAA gene in a Finnish late-onset Pompe disease patient: clinical phenotype and follow-up with enzyme replacement therapy. Korpela MP; Paetau A; Löfberg MI; Timonen MH; Lamminen AE; Kiuru-Enari SM Muscle Nerve; 2009 Jul; 40(1):143-8. PubMed ID: 19472353 [TBL] [Abstract][Full Text] [Related]
17. Pompe disease: design, methodology, and early findings from the Pompe Registry. Byrne BJ; Kishnani PS; Case LE; Merlini L; Müller-Felber W; Prasad S; van der Ploeg A Mol Genet Metab; 2011 May; 103(1):1-11. PubMed ID: 21439876 [TBL] [Abstract][Full Text] [Related]
18. Clinical features of Pompe disease. Manganelli F; Ruggiero L Acta Myol; 2013 Oct; 32(2):82-4. PubMed ID: 24399863 [TBL] [Abstract][Full Text] [Related]
19. Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy. Katzin LW; Amato AA J Clin Neuromuscul Dis; 2008 Jun; 9(4):421-31. PubMed ID: 18525427 [TBL] [Abstract][Full Text] [Related]
20. Fractures in children with Pompe disease: a potential long-term complication. Case LE; Hanna R; Frush DP; Krishnamurthy V; DeArmey S; Mackey J; Boney A; Morgan C; Corzo D; Bouchard S; Weber TJ; Chen YT; Kishnani PS Pediatr Radiol; 2007 May; 37(5):437-45. PubMed ID: 17342521 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]